Vesikari 1986a.

Methods	Randomization: coded list of the 2 vaccines Allocation concealment: code not broken until end of trial Blinding: double (parents and paediatricians unaware of the code) Data collection: vaccination between 10 December 1984 and 17 December 1984, no further details Intention to treat: no Interim analysis: none Exclusion from analysis: 2/51 excluded for lost incomplete data Follow‐up period: 7 days after vaccination
Participants	Age: 8 months Health status: healthy Breastfeeding: no information Immunization status: no information
Interventions	1. Bovine (RIT 4237), 10^8.3 TCID50, single dose (n = 24) 2. Rhesus (MMU18006), 10^5 PFU, single dose (n = 25) Ordinary meal or breast milk given before vaccines
Outcomes	1. Safety: clinical symptoms within 7 days of vaccination
Notes	Study location: Finland Clinical symptoms: clinical evaluation, no definitions given Laboratory studies: serology by ELISA CF and plaque reduction neutralization assay; stool analysis by ELISA